Comparison between intravenous chemotherapy and intra-arterial chemotherapy for retinoblastoma: a meta-analysis

• Published in: BMC cancer 2018-04, Vol.18 (1), p.486-486, Article 486
• Main Authors: Chen, Qiuying, Zhang, Bin, Dong, Yuhao, Mo, Xiaokai, Zhang, Lu, Huang, Wenhui, Jiang, Hua, Xia, Jiejun, Zhang, Shuixing
• Format: Article
• Language: English
• Subjects: Care and treatment; Chemotherapy; Diagnosis; Intra-arterial chemotherapy; Intravenous chemotherapy; Meta-analysis; Mutation; Retinoblastoma
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-018-4406-6

Intravenous chemotherapy (IVC) and intra-arterial chemotherapy (IAC) have become the primary treatments for retinoblastoma; however, some controversy remains over which method is more effective. We conducted a meta-analysis to compare the clinical efficacy of IVC and IAC. We systematically searched literature published on PubMed, Embase, and Cochrane Library up to May 2017. Studies containing either IAC or IVC that reported on efficacy were included. The effects estimate was expressed as a pooled rate with 95% confidence interval (CI), using a fixed-effects or random-effects model. Twenty-six studies were identified which included 1541 eyes (IAC: 11 trials, 445 eyes; IVC: 16 trials, 1096 eyes). The mean follow-up times were 49.4 months (range, 13.0-105.3 months) for IVC and 21.7 months (range, 8.8-38.7 months) for IAC. For the International Classification of Intraocular Retinoblastoma (ICRB) grading, the overall success rate was higher with IAC than with IVC (75.7% [95%CI: 65.7%-83.6%] vs. 69.5% [95%CI: 51.9%-82.8%], P